CLRB vs. CUE, KLRS, RENB, VRCA, HOWL, BLUE, IPA, IPSC, RNXT, and AADI
Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Cue Biopharma (CUE), Kalaris Therapeutics (KLRS), Renovaro (RENB), Verrica Pharmaceuticals (VRCA), Werewolf Therapeutics (HOWL), bluebird bio (BLUE), ImmunoPrecise Antibodies (IPA), Century Therapeutics (IPSC), RenovoRx (RNXT), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry.
Cellectar Biosciences vs. Its Competitors
Cellectar Biosciences (NASDAQ:CLRB) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.
Cellectar Biosciences has a net margin of 0.00% compared to Cue Biopharma's net margin of -507.87%. Cue Biopharma's return on equity of -228.43% beat Cellectar Biosciences' return on equity.
16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 5.0% of Cellectar Biosciences shares are held by insiders. Comparatively, 12.3% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Cellectar Biosciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.
In the previous week, Cellectar Biosciences had 9 more articles in the media than Cue Biopharma. MarketBeat recorded 13 mentions for Cellectar Biosciences and 4 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.61 beat Cellectar Biosciences' score of 0.52 indicating that Cue Biopharma is being referred to more favorably in the news media.
Cue Biopharma has higher revenue and earnings than Cellectar Biosciences. Cue Biopharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Cellectar Biosciences currently has a consensus target price of $375.00, suggesting a potential upside of 7,678.47%. Cue Biopharma has a consensus target price of $3.00, suggesting a potential upside of 336.05%. Given Cellectar Biosciences' higher probable upside, equities research analysts plainly believe Cellectar Biosciences is more favorable than Cue Biopharma.
Summary
Cue Biopharma beats Cellectar Biosciences on 11 of the 15 factors compared between the two stocks.
Get Cellectar Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectar Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CLRB) was last updated on 7/7/2025 by MarketBeat.com Staff
